BQ Prime's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BQ Prime's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
We like Alkem Laboratories Ltd. for its steady India business, strong balance sheet and high cashflows.
While we see unprecedented challenges in terms of high input cost in near term; increasing medical representative productivity in India business and ramping up launches in U.S. and international business would give comfort to Alkem Labs' earnings in long term.
We expect revenue/Ebitda/profit after tax compound annual growth rate of 11%/10%/7% over FY22-24E on high base.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
